CytoSorbents Showcases Blood Purification Innovations at H.C. Wainwright Conference

CytoSorbents Advances in Blood Purification Technologies Amid Industry Demand

CytoSorbents Corporation, a leader in the field of blood purification for critical care and cardiac surgery, highlights its commitment to addressing urgent medical needs through innovative technologies. With the upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, the company plans to showcase its groundbreaking advancements in blood purification. The conference, set to take place at the Lotte New York Palace Hotel, presents a pivotal platform for CytoSorbents to engage with investors and industry experts while emphasizing its vital role in improving patient outcomes.

At the core of CytoSorbents' offerings is the CytoSorb® device, which utilizes biocompatible, highly porous polymer beads to effectively remove harmful substances from blood and bodily fluids. This innovative technology operates seamlessly with standard hospital blood pumps, enabling continuous recirculation of blood through the cartridges. The applications of CytoSorb® are particularly significant in high-risk surgical settings, such as cardiothoracic procedures, where the removal of blood thinners is crucial to minimize bleeding. Additionally, the device plays a critical role in treating severe conditions like sepsis and trauma, where the quick elimination of inflammatory agents can substantially reduce mortality risks.

CytoSorb® has gained considerable traction in the medical community, with over 300,000 devices deployed across more than 70 countries. Initially recognized as the first cytokine adsorber in the European Union, the product has seen its CE mark extended for numerous applications, including the removal of bilirubin and myoglobin. The FDA has also granted Emergency Use Authorization for its essential applications in the United States. As the healthcare landscape continues to evolve, CytoSorbents' focus on enhancing its blood purification technologies positions the company as a key player in delivering life-saving interventions for critically ill patients.

In addition to its conference participation, CytoSorbents’ ongoing commitment to research and development paves the way for future innovations in blood purification. The company continues to explore new therapeutic applications and expand its product offerings, reinforcing its mission to improve patient care during critical medical situations. This dedication not only strengthens its market position but also highlights the importance of effective blood purification solutions in modern medicine.